Enlivex Therapeutics (Nasdaq: ENLV) Revenue
Pharmaceutical Manufacturing • 
Nes Ziona, Center District, Israel • 21-50 Employees
Enlivex Therapeutics (Nasdaq: ENLV) revenue & valuation
| Annual revenue | $2,994,425 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $9,600,000 |
| Total funding | $6,200,000 |
Key Contacts at Enlivex Therapeutics (Nasdaq: ENLV)
Sigal Arad
Human Resources Director
Lital Weinfeld Bergman
Senior Director Clinical Operations
Chen Ankri
Director Of Pre Clinical And Clinical Pharmacology
Lior Binder
Clinical Study Director
Idan Cohen
Director Of Production And Supply Chain
Adi Shani
Director Of Qa
Company overview
| Headquarters | 14 Einstein St., Nes-Ziona, Israel 7403618, IL |
| Phone number | +9727403618 |
| Websites | |
| NAICS | 3254 |
| SIC | 873 |
| Employees | 21-50 |
| Socials |
Enlivex Therapeutics (Nasdaq: ENLV) Email Formats
Enlivex Therapeutics (Nasdaq: ENLV) uses 4 email formats. The most common is {first name} (e.g., john@enlivexpharm.com), used 62.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@enlivexpharm.com | 65.6% |
{first initial} | j@enlivex.com | 28.1% |
{first initial}{last name} | jdoe@enlivexpharm.com | 6.2% |
About Enlivex Therapeutics (Nasdaq: ENLV)
Our mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body’s native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated. Highlights: * Advanced clinical-stage pipeline with promising Phase II results * Short regulatory approval pathway * Multi-billion-dollar markets: Post-BMT complications , Sepsis, Solid tumors
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Enlivex Therapeutics (Nasdaq: ENLV) has 19 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Enlivex Therapeutics (Nasdaq: ENLV)'s funding history, including investment rounds, total capital raised, and key backers.
Enlivex Therapeutics (Nasdaq: ENLV) Tech Stack
Discover the technologies and tools that power Enlivex Therapeutics (Nasdaq: ENLV)'s digital infrastructure, from frameworks to analytics platforms.
Security
Miscellaneous
JavaScript libraries
JavaScript libraries
Page builders
CDN
Web servers
Font scripts
JavaScript libraries
Programming languages
Blogs
United Kingdom
United States
Mexico
India
South Africa
Frequently asked questions
4.8
40,000 users
